Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEA-NK Infusion Post Haplo-SCT for Refractory Myeloid Malignancies
NCT05375253Phase 1Withdrawn
- Sponsor
- University of Nebraska
- Start
- Apr 2023
- Primary completion
- Apr 2023
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
Phase 1, open-label, single-arm trial of Donor Enriched Activated Natural Killer cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN), sponsored by University of Nebraska. Primary endpoints: Percent of successful DEA-NK cell infusions at 100 Days, Number of adverse events for those who have a DEA-NK cell infusion at 100 Days and 1 more. Planned start Apr 2023; status: withdrawn.
02
Drugs
Donor Enriched Activated Natural Killer cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT05375253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05375253.